ZP
CRNX icon

Zimmer Partners’s Crinetics Pharmaceuticals CRNX Stock Holding History

Zimmer Partners’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-28,700
Closed -$1.02M – 136
2023
Q4 		$1.02M Buy
28,700
+13,700
+91% +$420K 0.04% 92
2023
Q3 		$446K Buy
+15,000
New +$309K 0.01% 117
2018
Q4 		– Sell
-10,000
Closed -$287K – 81
2018
Q3 		$287K Buy
+10,000
New +$297K ﹤0.01% 95

Other funds holding CRNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Zimmer Partners's CRNX Position: Q1 2024 in Review

Zimmer Partners sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2024, closing a stake of 28,700 shares — an estimated $1.02M sold.

Zimmer Partners first reported a position in CRNX in Q3 2018 and held it in 3 quarters. The position peaked at $1.02M in Q4 2023. 203 funds tracked by Wall St. Rank hold CRNX as of Q1 2024.

  • Zimmer Partners reported no remaining Crinetics Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Zimmer Partners sold 28,700 Crinetics Pharmaceuticals shares in Q1 2024, an estimated $1.02M.
  • Zimmer Partners first reported a position in Crinetics Pharmaceuticals in Q3 2018 and held it in 3 quarters.
  • Zimmer Partners's Crinetics Pharmaceuticals position peaked at $1.02M in Q4 2023.
  • 203 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2024.

Based on Zimmer Partners's 13F filing for Q1 2024, filed 15 May 2024.